Global Research & Innovation Initiatives and Programme Opportunities
Return to overview

United States Biomedical Advanced Research and Development Authority (BARDA)

Initiative/Organisation

Biomedical Advanced Research and Development Authority (BARDA)

Goal

Within the US Administration for Strategic Preparedness and Response, the Biomedical Advanced Research and Development Authority (BARDA) invests in advanced research and development, acquisition, and manufacturing of medical countermeasures needed to combat health security threats – including vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products. BARDA’s active areas of interest (AOIs) include antimicrobial resistance (AMR) and influenza and emerging infectious diseases (IEID).

Open opportunities

BARDA publishes calls for proposals on:

Easy Broad Agency Announcement (EZ-BAA)
BARDA’s Easy Broad Agency Announcement (EZ-BAA) sets forth AOIs for the Division of Research, Innovation, and Ventures (DRIVe) and seeks abstracts for efforts to develop revolutionary health security products, technologies, and innovations in order to increase the Government’s capability and capacity to respond to national security health threats.

Broad Agency Announcement (BAA)
BARDA’s Broad Agency Announcement (BAA) solicits proposals for the advanced research and development of medical countermeasures (MCMs) such as vaccines, therapeutics, diagnostics, and devices. The BAA is intended for advanced research and development of MCMs to counter chemical, biological, radiological, and nuclear threats; pandemic influenza; and emerging infectious diseases.

Open EZ-BAA and BAA funding opportunities are listed on SAM.gov. In order to submit your application, you will be required to apply for a 1) SAM.gov account as well as a 2) BDR Portal account. You will then submit your application through the BDR Portal.

ASPR grant opportunities
Open grant opportunities are listed on grants.gov.

Please see below for more information about open opportunities.

Call for proposals

There are currently five funding opportunities under EZ-BAA:

Application deadline
  • ReDIRECT: 31 March 2025 at 12:00 PM ET
  • Healing Lungs: 28 February 2025 at 12:00 PM ET
  • ReBooT: 30 April 2025 at 12:00 PM ET
  • ImmuneChip+: 28 September 2028 12:00 PM ET
  • Influenza Vaccine Innovation: 20 January 2025 at 12:00 PM ET
Next round of applications
  • EZ-BAA: For further information on the anticipated future calls for proposals, click here.
  • BAA: For further information on the anticipated future calls for proposals, click here.
  • ASPR grant opportunities: For further information on the anticipated future calls for proposals, click here.
Opportunity type

Depending on the specific opportunity

Eligibility criteria
  • EZ-BAA
    EZ-BAA is open to all responsible sources, both domestic and international. Respondents may include single entities or teams from private sector organizations, not-for-profit organisations, nongovernmental organizations, and academic institutions. BARDA DRIVe strongly encourages submissions from small businesses, historically black colleges and universities, minority institutions and minority researchers
  • BAA
    The BAA is open to single entities or teams from private sector organizations, government laboratories, and academic institutions are eligible to submit a proposal.
    EZ-BAA and BAA respondents must be registered in the System for Award Management (SAM) with the appropriate North American Industry Classification System code prior to proposing their submission. Registration can be completed on SAM.gov.
  • ASPR grant opportunities
    There are many types of organisations generally eligible to apply for funding opportunities on Grants.gov. Each type of organization listed in the categories below is a specific search criterion in Search Grants. 
Intellectual property policy

Depending on the specific opportunity

Funding level
  • EZ-BAA: EZ-BAA funding is under USD 750,000, and including a cost-share element. Respondents who have received an award under the EZ-BAA also have an opportunity to apply to the Plus (+) Phase of the EZ-BAA which allows for an additional award valued up to USD 20 million.
  • BAA: BAA funding varies depending on the specific solicitation.
  • ASPR grant opportunities: The amount of ASPR grant funding varies depending on the specific solicitation.
Find out more
  • EZ-BAA: For further information on the EZ-BAA application process, please click here.
  • BAA: For further information on the BAA application process, please click here.
  • ASPR grant opportunities: For further information on the grant application process, please click here.
Return to overview

This tool was created by FTI Consulting for GSK and EFPIA.
For all enquiries please contact niro@fticonsulting.com
Privacy policy

This tool was created by FTI Consulting
for GSK and EFPIA.
For all enquiries please contact niro@fticonsulting.com
Privacy policy

What type of funding are you looking for?

  • Grant:
    Grants are direct financial contributions from the European Union budget awarded by way of a donation to third-party beneficiaries (usually non-profit-making organisations) engaged in activities that serve EU policies.
  • Loan:
    Loans are measures of financial support provided on a complementary basis from the budget in order to address specific policy objectives of the European Union. Such instruments are implemented in partnership with public and private institutions such as banks, venture capitalists or angel investors.

What stage of development are you seeking R&I funding for?

  • Basic science: Basic science covers the various exploratory steps even prior to discovery
  • Discovery: Drug discovery aims to find potential disease-altering targets, such as a gene or a protein in humans. Prior to testing candidate compounds for safety
  • Preclinical development: Preclinical development concerns the testing of candidate compounds for safety in specific indications or disease conditions. Introduction of candidate compound in living biological systems (animals)
  • Phase 1 clinical trials: These are the first clinical trials on humans(usually 20-80 volunteers) testing the safety, side effects, best dose, and timing of a new treatment
  • Phase 21/2b clinical trials: This is the follow-up trial with roughly 100 to 500 patients to analyse efficacy and safety
  • Phase 3 clinical trials: These trials usually involve several hundreds to many thousands patients and tests the results of earlier clinical trials on larger populations to generate robust data on safety, efficacy and benefit-risk relationships of the medicine. Comparison to placebo and/or active comparator (best standard treatment)
  • Registration & launch: This concerns post-study, prior to launch, activities related to market launch. That can include, among others, marketing authorisation, regulatory activities, post-study communication or HTA
  • Introduction & delivery: This concerns all post-launch activities

What do you want to develop?

  • Treatment or vaccine:
    Refers to a drug or vaccine
  • Diagnostic or medical device:
    Refers to diagnostics and medical devices
  • Platform:
    Refers to a digital health platform or medical app
  • Knowledge:
    Refers to conducting research to help build our understanding on a topic
  • Standards:
    Refers to creating a benchmark for a specific issue

What type of organisation are you?

  • Small & medium-sized enterprises:
    <250 employees, annual revenue <EUR 50,000,000) or balance sheet < EUR43 million. This applies to individual firms only. If part of larger group, check the User Guide: https://ec.europa.eu/docsroom/documents/42921
  • Large enterprises:
    >250 employees or annual revenue > EUR 50,000,000. Non-profit organisation (non-governmental organisations that are recognised with a non-profit status)
  • Non-profit organisations:
    Non-governmental organisations that are recognised with a non-profit status
  • Academic:
    Linked to a university or equivalent
  • Public:
    Local, regional, federal government representative

What stage of diagnostics development does your research aim to cover?

  • Development:
    Product development
  • Validation:
    Lab and clinical validation
  • Evaluation & Authorisation:
    Regulatory approvals
  • Access:
    Monitoring

What stage of medicine or vaccine development does your research aim to cover?

  • Discovery and development:
    Identification of promising compounds for development and initial experiments to gather information
  • Preclinical research:
    Laboratory and animal testing to answer basic questions about safety
  • Phase 0 (clinical):
    Testing on limited number of subjects at subtherapeutic doses
  • Phase I (clinical):
    Testing on <100 healthy subjects with the disease/condition
  • Phase II (clinical):
    Testing on up to several hundred subjects with the disease/condition
  • Phase III (clinical):
    Testing on 300 to 3,000 volunteers with the disease/condition
  • Preregistration / Phase IV (clinical):
    Testing on several thousand volunteers with the disease/condition
  • Clinical (unspecified):
    Clinical phase unknown
  • Evaluation & Authorisation:
    Activities relating to marketing authorisation
  • Access:
    Monitoring

Where are you based?

  • Africa : Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic (CAR), Chad, Comoros, Congo (Democratic Republic of the), Congo (Republic of the), Cote d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe
  • America (non-US & Canada) : Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela
  • Asia-Pacific : Afghanistan, Australia, Bangladesh, Bhutan, Burma, Brunei, Cambodia, China (including special administrative regions of Hong Kong and Macau), Cook Islands, Federated States of Micronesia, Fiji, India, Indonesia, Japan, Kiribati, Laos, Malaysia, Maldives, Marshall Islands, Mongolia, Nepal, New Caledonia, New Zealand, Niue, North Korea, Pakistan, Palau, Papua New Guinea, Philippines, Singapore, Solomon Islands, South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste, Tonga, Tuvalu, Vanuatu, Vietnam
  • Europe (non-EU) : Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Iceland, Kosovo, Liechtenstein, Moldova, Monaco, Montenegro, North Macedonia, Norway, Russia, San Marino, Serbia, Switzerland, Turkey, Ukraine, United Kingdom
  • European Union (EU) : Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
  • Middle East : Cyprus, Lebanon, Syria, Iraq, Iran, Israel, Jordan, Saudi Arabia, Kuwait, Qatar, Bahrain, United Arab Emirates, Oman, Yemen
  • United States (US) & Canada : United States, Canada

What type of organisation are you?

  • Small and medium-sized enterprise (SME):
    Staff headcount 50 < and turnover ≤ EUR 10 m or balance sheet total ≤ EUR 10 m (small); Staff headcount 250 < and turnover ≤ EUR 50 m or balance sheet total ≤ EUR 43 m (medium)
  • Large enterprise:
    Staff headcount > 250
  • Non-profit organisation:
    Association, foundation, or equivalent
  • Academic:
    University, research institute, or equivalent
  • Individual:
    Private citizen
  • Public sector:
    Local, regional, federal government representative
  • Other:
    None of the above or uncertain